• 1996 Young Researcher Award from the Bettencourt-Schueller Foundation
• 2013 Grand Challenge Canada (Intranasal nicotine vaccine, GCC S4 0212-01)

• PCT/US20120177683 - Methods for Preparing Vesicles and Formulation Produced Therefrom, Inventor: David Evander Anderson, Hoang-Thanh Le and Francisco J. Diaz-Mitoma, Variation Biotechnologies Inc., filed on July 12, 2012.
• PCT/US20110177163A1 - Compositions and Methods for Treating Hepatitis A, Inventor: Francisco J. Diaz-Mitoma and Hoang-Thanh Le., Variation Biotechnologies Inc., filed on July 21, 2011.
• PCT/US2010/61685 - Compositions and methods for treating influenza, Inventor: David Evander Anderson, Francisco J. Diaz-Mitoma, Hoang-Thanh Le and Andrei Ogrel., Variation Biotechnologies Inc., filed on December 10, 2010.
• US Patent 7183279 (2007) - Histogranin-like peptides and non-peptides, processes for their preparation and uses thereof (Inventor: Lemaire, Simon; Bernatchez-Lemaire, Irma; Le, Hoang-Thanh, University of Ottawa.
• US Patent 7074786 (2006) - Histogranin-like peptides, processes for their preparation and uses thereof (Inventor: Lemaire, Simon; Bernatchez-Lemaire, Irma; Le, Hoang-Thanh, University of Ottawa.
• US Patent 6972281 (2005) - Histogranin-like peptides, processes for their preparation and uses thereof (Inventor: Lemaire, Simon; Bernatchez-Lemaire, Irma; Le, Hoang-Thanh, University of Ottawa.

• David Goyard, Tze Chieh Shiao, Nya L. Fraleigh, Francisco Diaz-Mitoma, Hoang-Thanh Le and René Roy*. Expedient Synthesis of Functional Single-Molecule Glycoliposomes Using Thiol-yne Chemistry, Journal of Materials Chemistry B, submitted on Feb 08, 2016 (Manuscript ID: TB-ART-02-2016-000344)
• Trần Khánh Linh, Nguyễn Thị Yến Nhi, Lê Hà Tầm Dương, Đặng Trịnh Minh Anh, Francisco Diaz-Mitoma, Hoang-Thanh Le*, Cao Thị Bảo Vân*. Initial Evaluation of Immunogenicity and Safety of Intranasal Nicotine Vaccine on Animal Models. Journal of Preventive Medicine (2015), 165, 360-365
• Azizi* A, Ghunaim H, Sirskyj D, Fallahi F, Le* H.-T. and Kumar A. Delivery of immunogens to mucosal immune system using an oral inactivated cholera vaccine: A new approach for development of oral vaccines. Human vaccines and Immunotherapeutics (2013), 9, 1-4.
• Ali Azizi, Danylo Sirskyj, Amine Saad, Andrei Ogrel, Hoang Thanh Le, Catalina Soare, David E Anderson, Jose Torres and Francisco Diaz-Mitoma. Induction of dendritic cell maturation by a liposomally-delivered multivalent HIV vaccine. Retrovirology. (2009), 6, P330.
• Lemaire, Simon, Trinh, TT, Le, Hoang-Thanh, Tang, SC, Hincke, M, Wellman-Labadie O, Ziai, S. Antimicrobial effects of H4-(86-100), histogranin and related compounds - possible involvement of DNA gyrase. The FEBS Journal (2008), 275, 5286-5297.
• René Poirier, Irma Lemaire, Michel Dumont, Natacha Leduc, Hoang-Thanh Le, and Simon Lemaire. Correlation between the expression of the histone H4 mRNA variant H4-v.1 and the levels of the C-terminal histone H4 peptides OGP and H4-(86-100) in various rat tissues and isolated alveolar macrophages. Peptides. (2005), 26, 1503-1511.
• Hoang-Thanh Le, Irma Lemaire, Annie-Kim Gilbert, François Jolicoeur, Natacha Leduc, Lin Yang and Simon Lemaire. Histogranin-like Antinociceptive and Anti-Inflamatory Derivatives of o-Phenylenediamine and Benzimidazole. J. Pharmacol. Exp. Ther. (2004), 309, 146-155.
• Hoang-Thanh Le, Irma Lemaire, Annie-Kim Gilbert, François Jolicoeur, and Simon Lemaire. Bioactive peptidic analogues and Cyclostereoisomers of the minimal antinociceptive Histogranin fragment-(7-10). J. Med. Chem. (2003), 46, 3094-3101.

Dr. Le’s expertise are in the  development of new immunotherapy strategies for invention and treatment of drug addiction and new mucosal adjuvant approach in treatment of chronic disease.

In order to contribute to the cessation of smoking to reduce health risks and improve environmental conditions, Dr. Le proposes a novel mucosal nicotine vaccine approach that can be delivered through the nose and skin routes. This strategy aims to block nicotine inhaled from cigarettes at the lung tissue before it reaches the bloodstream because it not only induces IgG in the blood, but also produces IgA, which will offer another line of defense for the brain.

The new mucosal vaccine is produced in a freeze-dried formulation that facilitates vaccine storage and transport and it offers an affordable, pain-free and easy delivery to patients. This platform is not only ideal for tobacco addiction, but can also be deployed to other drug addiction treatment applications, such as cocaine, methamphetamine and heroin treatment.

Chronic diseases, including diabetes, obesity, and heart disease, have high potential impacts not only in developed countries, but also in low and middle income countries. More than 35 million people worldwide died from chronic diseases every year. Dr. Le’s research also investigates new mucosal adjuvant approach in treatment of chronic disease. There is promising proof to use immunodrugs to reduce blood pressure in hypertensive patients or blood sugar levels in patients with type 2 diabetes. We are developing the new bacteria-derived particles/self-assembled lipid peptides as an adjuvant system for non-injection immunotherapy to prevent or treat the chronic disease (LPS target).